BEIJING--(BUSINESS WIRE)--BeiGene (Beijing), Co., Ltd., an innovative oncology company focused on developing targeted and immune-oncology therapeutics, today announced that it has dosed the first patient in a Phase 1 study of BGB-290 for the treatment of cancer. BGB-290 is an investigational, oral, selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP), an enzyme family which is involved in a number of cellular processes, including DNA repair and programmed cell death.
Help employers find you! Check out all the jobs and post your resume.
